FDA Approves Penpulimab for Non-Keratinizing Nasopharyngeal Carcinoma

The FDA has approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.